Want to see LIVN full AI Analyst Report?
LIVN Stock Chart & Stats
$67.12
$0.70(1.49%)
At close: 4:00 PM EST
$67.12
$0.70(1.49%)
Day’s Range― - ―
52-Week Range$41.02 - $80.96
Previous CloseN/A
Volume66.13K
Average Volume (3M)797.49K
Market Cap
$4.59B
Enterprise Value$4.11B
Total Cash (Recent Filing)$539.70M
Total Debt (Recent Filing)$334.50M
Price to Earnings (P/E)42.4
Beta0.97
Next Earnings
Aug 05, 2026EPS Estimate
1.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.97
Shares Outstanding54,933,537
10 Day Avg. Volume846,345
30 Day Avg. Volume797,486
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.79
Price to Sales (P/S)2.42
P/FCF Ratio19.36
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue2.87
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda19.04
Forecast
1Y Price Target
$81.88Price Target Upside21.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)4.25
Revenue Forecast (FY)$1.51B
Bulls Say, Bears Say
Bulls Say
Cardiopulmonary Momentum & Manufacturing ScaleGreater Essenz penetration and planned manufacturing expansion support durable, recurring consumables pull-through tied to cardiac procedures. Market-share gains in HLM placements and higher output capacity reduce supply constraints, underpin sustainable revenue and margin expansion in cardiopulmonary over the medium term.
Regulatory & Clinical Differentiation In OSAPMA approval and robust RCT evidence materially improve commercial prospects and payer conversations for HGNS. Strong clinical data and no CCC-related contraindication increase addressable patient population, ease market access and support durable adoption, pricing power and reimbursement negotiations over years.
Improved Cash Generation And LeverageSolid operating cash flow combined with a lower debt burden provides financial flexibility to fund R&D, manufacturing capacity, and targeted M&A while absorbing reimbursement or supply shocks. Sustained cash generation strengthens liquidity and strategic optionality across medium-term investment cycles.
Bears Say
Earnings VolatilityLarge swings in annual profitability indicate sensitivity to one-time items, reimbursement shifts and operational execution. Persistent volatility hampers forecasting, makes capital allocation harder, and can undermine investor and counterparty confidence if repeated, raising the risk profile over multiple reporting periods.
Near-term Free Cash Flow PressureElevated capex and a working-capital build reduce free cash flow conversion and limit cash available for discretionary returns. If investment intensity persists or FCF remains variable, it constrains buybacks/dividends and increases reliance on debt or equity to fund growth or to smooth cash flow across cycles.
Supply Constraints & BackordersOngoing supplier bottlenecks cap near-term revenue and impede the company from fully realizing market-share and consumable volume gains. Persistent production or supplier issues can raise costs, delay placements, and force incremental investment in capacity or sourcing, weighing on durable margin improvement.
LivaNova News
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $41.02 and its highest was $80.95 in the past 12 months.
What is LivaNova PLC’s market cap?
LivaNova PLC’s market cap is $4.59B.
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Aug 05, 2026 which is in 30 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on May 06, 2026. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.897 by $0.083.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is 1.09.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,933,537 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.98 in its last earnings report, beating expectations of $0.897. Following the earnings report the stock price went up 15.055%.
Which hedge fund is a major shareholder of LivaNova PLC?
Currently, no hedge funds are holding shares in LIVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$81.88 (21.98% Upside)
$81.88 (21.98% Upside)
Blogger Sentiment
Bullish
LIVN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 874.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.1%
Last 30 Days ▲ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
81.46%
12-Months-Change
Fundamentals
Return on Equity
9.13%
Trailing 12-Months
Asset Growth
-1.66%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
LIVN Company Deck
LIVN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered multiple material positive developments: double-digit Q1 revenue growth, upward revisions to full-year revenue and EPS guidance, regulatory approval and robust clinical evidence in OSA, meaningful reimbursement improvement for VNS in the U.S., strong cardiopulmonary momentum (Essenz upgrade and manufacturing expansion) and clinical differentiation (PolySync). Headwinds exist—near-term cash and free cash flow pressures driven by higher capex, working capital and a one-time bonus payout; modest gross margin compression; ongoing third-party supply constraints and reimbursement/coding uncertainty for HGNS and DTTD—which the company is actively addressing. On balance, the positives (revenue/earnings upgrades, regulatory/clinical milestones, market share gains and manufacturing expansion plans) outweigh the lowlights, indicating strong operational momentum while the company invests for growth and manages known near-term pressures.View all LIVN earnings summariesLIVN Stock 12 Month Forecast
Average Price Target
$81.88
▲(21.98% Upside)
Technical Analysis
Artivion
―
Integer Holdings
―
Ufp Technologies
―
Inspire Medical Systems
―
TransMedics Group
―
Ownership Overview
0.40% Insiders
37.02% Mutual Funds
0.07% Other Institutional Investors
37.87% Public Companies and
Individual Investors